CAN
Canaan Inc.
Next earnings Aug 12, 2026 · consensus $-0.06 EPS, $53.9M rev
$0.28
▼ -4.90%$0.28▼ -52.32%
over 1Y
L $0.28H $2.05
Today-4.9%
1W-4.6%
1M-28.0%
3M-32.3%
YTD-63.2%
1Y-52.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Revenue grew 96.7% YoY; but unprofitable (net margin -39.7%).
Revenue (FY2025) $530M · FY2025
Canaan Inc. shows $530M in FY2025 revenue (+96.7% YoY), a -39.7% net margin, and -48.1% ROE.
Supporting the case: revenue grew 96.7% YoY; conservative balance sheet (liabilities/equity 0.38x).
Is CAN a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~0.28
- Short call 0.5 @ ~0.00 est
debit $28max +$22max −$27BE 0.28
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $773M | $652M | $211M | $269M | $530M |
| Gross profit | $442M | $230M | -$241M | -$84.3M | $41.2M |
| Operating income | $283M | $42.9M | -$411M | -$227M | -$112M |
| Net income | $309M | $69.9M | -$414M | -$250M | -$210M |
| Diluted EPS | $12.00 | $2.71 | -$16.06 | -$6.13 | -$2.99 |
| Net margin | 40.0% | 10.7% | -195.8% | -92.7% | -39.7% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$183M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-99.5%
FCF yield-140.0%
Quality & risk
ROIC (est.)-18.1%
Free cash flow-$296M
Total debt$52.2M
Net cash$28.5M
Altman Z-Score0.10 distress
Piotroski F-Score4/9
Capital returns
Buyback yield2.4%
Dividend yield (est.)—
Shareholder yield2.4%
Shares Δ YoY+72.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-242026-06-24open ↗4Period ending 2026-06-172026-06-22open ↗EFFECTFiling2026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗POS AMFiling2026-06-16open ↗POS AMFiling2026-06-15open ↗6-KPeriod ending 2026-06-112026-06-11open ↗SCHEDULE 13GFiling2026-06-05open ↗POS AMFiling2026-05-22open ↗6-KPeriod ending 2026-05-192026-05-19open ↗6-KPeriod ending 2026-05-192026-05-19open ↗
Frequently asked
- Is Canaan Inc. (CAN) a buy?
- CAN currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 96.7% YoY; but unprofitable (net margin -39.7%).
- What is Canaan Inc.'s quality score?
- CAN scores 56.4516516697811/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001780652, latest 6-K filed 2026-06-24) · EODHD · as of 7/5/2026, 12:20:33 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 8:20 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.